Home・Aandelen Lijst・Bristol-Myers Squibb Co.

Bristol-Myers Squibb Co.

Gesloten

SectorGezondheidszorg

64.69 0.9

Buy Sell

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

63.72

Max

64.7

Belangrijke statistieken
By Trading Economics
Inkomsten	638M 3.3B
Verkoop	1.5B 13B
K/W Sectorgemiddelde	14.421 68.51
EPS	2.04
Dividendrendement	3.84
Winstmarge	25.561
Werknemers	32,500
EBITDA	1.3B 4.9B

Aanbevelingen
By TipRanks
Aanbevelingen	Buy
12 Maanden Prognose	+3.35% upside

Dividenden
By Acuity
Dividendrendement Sectorgemiddelde	3.84% 2.29%
Volgende Winsten	29 okt 2026
Volgende Ex Dividend datum	2 okt 2026

Marktinformatie
By TradingEconomics
Marktkapitalisatie	6B 134B
Vorige openingsprijs	63.79
Vorige sluitingsprijs	64.69

Nieuwssentiment

By Acuity

40%

60%

137 / 340 Rangschikking in Healthcare

Bristol-Myers Squibb Co. Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

6 aug 2026, 23:26 UTC

Bristol-Myers Squibb Co shares are lower in after-market hours, influenced by broader market trends and a stronger U.S. Dollar amid rising jobless claims.

5 aug 2026, 23:01 UTC

Bristol-Myers Squibb Co shares are lower in after-market hours. No specific news was identified to explain the movement.

4 aug 2026, 23:16 UTC

Bristol-Myers Squibb Co. shares gained in after-market trading, reflecting a modest uptick of 0.20% and remaining above their 20-day moving average.

3 aug 2026, 23:02 UTC

Bristol-Myers Squibb Co shares are lower in after-market hours, with no specific news identified to explain the movement. The stock remains above its 20-day moving average.

31 jul 2026, 19:16 UTC

News

Social Media

Bristol-Myers Squibb shares rise as multiple analysts raise price targets following strong second-quarter results and an upward revision of annual guidance.

30 jul 2026, 22:51 UTC

Bristol-Myers Squibb Co. shares are lower in after-market trading, reversing earlier gains and reflecting a notable retreat from earlier highs.

29 jul 2026, 23:36 UTC

Bristol-Myers Squibb Co shares are higher in after-market trading, amid rising interest rates and inflation concerns contributing to market volatility. No specific news was identified.

28 jul 2026, 20:06 UTC

News

Bristol-Myers Squibb is rising as it enhances collaboration with Nvidia for AI in drug discovery, improving efficiency in development processes.

27 jul 2026, 22:01 UTC

Bristol-Myers Squibb Co shares are lower in after-market hours, with no specific news driving the decline amid mixed broader market performance.

24 jul 2026, 17:56 UTC

Bristol-Myers Squibb Co shares are higher, maintaining a positive trajectory since Thursday's close. No specific news was identified to explain today's price action.

23 jul 2026, 00:01 UTC

Bristol-Myers Squibb Co shares are modestly higher in after-market trading, recovering from an earlier dip and remaining above their 20-day moving average.

22 jul 2026, 23:11 UTC

Bristol-Myers Squibb Co shares are higher in after-market trading, reaching a notable rise while remaining above the 20-day moving average.

21 jul 2026, 23:36 UTC

Bristol-Myers Squibb Co. shares are near unchanged in after-market trading, remaining above their 20-day moving average amid a solid performance backdrop.

20 jul 2026, 23:41 UTC

Bristol-Myers Squibb Co. shares are trading roughly flat in after-market hours, remaining effectively unchanged since Monday's close amid no specific news.

Peer Vergelijking

Prijswijziging

Bristol-Myers Squibb Co. Prognose

Koersdoel

By TipRanks

3.35% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 66.3 USD 3.35%

Hoogste 80 USD

Laagste 40 USD

Gebaseerd op 21 Wall Street-analisten die 12-maands prijsdoelen bieden voor Bristol-Myers Squibb Co. - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Buy

21 ratings

Buy

Hold

Sell

Gebaseerd op 21 analisten die aandelenratings hebben gegeven aan Bristol-Myers Squibb Co. - Dist in de afgelopen 3 maanden.

Sentiment

By Acuity

137 / 340 Rangschikking in Gezondheidszorg

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

Over Bristol-Myers Squibb Co.

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia. It also provides Yervoy for the treatment of patients with unresectable or metastatic melanoma; Empliciti for the treatment of multiple myeloma; Abecma for the treatment of relapsed or refractory multiple myeloma; Reblozyl for the treatment of anemia; Opdualag for the treatment of unresectable or metastatic melanoma; and Zeposia to treat relapsing forms of multiple sclerosis. In addition, the company offers Breyanzi for the treatment of relapsed or refractory large B-cell lymphoma; Onureg for the treatment of AML; Inrebic for the treatment of myelofibrosis; Camzyos for the treatment of symptomatic obstructive HCM to enhance functional capacity and symptom; Sotyktu for the treatment of moderate-to-severe plaque psoriasis; Augtyro for the treatment of locally advanced or metastatic ROS1-positive NSCLC; Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; and Abraxane to treat breast cancer, NSCLC and pancreatic cancer. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in Princeton, New Jersey.